Rosemont Deal Shows Value Is Out There For US Exit, Perrigo Says

Planned Separation ‘Will Take Some Time’

 
• By Dean Rudge

Perrigo management provided colorful commentary on Perrigo’s latest endeavors to separate the company’s US generics business, following the recent sale of Perrigo’s Rosemont Pharmaceuticals subsidiary for an “attractive” multiple.

Value
Perrigo will keep hold of its Rx business until a suitable multiple can be found for its sale • Source: Shutterstock

More from Generics

More from Products